C019199

C019199 is an orally administered small molecule inhibitor designed to modulate the tumor immune microenvironment (TME) in order to enhance antitumor efficacy, particularly when combined with immune checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 therapies. It specifically inhibits colony-stimulating factor 1 receptor (CSF-1R), discoidin domain receptor 1 (DDR1), and vascular endothelial growth factor receptor 2 (VEGFR2) with high potency. Inhibition of CSF-1R can deplete tumor-associated macrophages, promoting T cell infiltration and response within tumors. Additional inhibition of DDRs and VEGFR2 helps disrupt the physical barrier created by the tumor extracellular matrix and normalizes tumor vasculature, further facilitating T cell infiltration. Preclinical studies have demonstrated that C019199 suppresses tumor growth in multiple animal models and shows enhanced efficacy when used in combination with immune checkpoint blockade therapies. The drug is currently being evaluated in phase I/II clinical trials for advanced solid tumors[1][4][5][7].

Other names

CSF-1R/DDR1/VEGFR2 inhibitor C019199